Precision medicine company Olaris announced this week that it has received a grant for an undisclosed amount from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). Olaris will use the funding to identify biomarkers that can detect Parkinson’s disease at its earliest onset.
"Recent scientific and biomedical advances in precision medicine are driving cloud-based data and technology strategies, closing the gap in our ability to translate advances into clinically validated diagnostics and therapeutics," Elaine Johanson, acting director of health informatics in FDA's within the Office of the Chief Scientist, said in a statement. "PrecisionFDA contributes to an optimized and independent review process by making tools available that empower reviewers to assess the accuracy of analytic pipelines without requiring bioinformatics expertise and enabling effective sponsor-reviewer interaction on a secure, cloud-based platform."
More than a decade after the immense promise unleashed by the completion of Human Genome Project, precision medicine has struggled with its own “last mile.” Despite major leaps in the field as a whole, the technical work needed to integrate a patient’s genomic information into the day-to-day practice of medicine has lagged far behind.
"Xcell Biosciences created the Technology Access Program (TAP) to accelerate the discovery of novel applications using our proprietary Primary Cell Control Systems in the field of Immunotherapy. We launched the TAP to collaborate with researchers and commercial partners in advancing the technology frontier of Human Microenvironments (HME) including Tumor Microenvironments (TME). We will provide the instrumentation and technical support necessary for partners to jointly invent and validate new discovery technology," said Janette Phi, COO. "Our solutions focus on clinical researchers developing therapies at the convergence of precision medicine, stem cell technology, and immunotherapy."
Precision medicine software firm LifeOmic has named Ed Simcox as its new chief strategy officer. Simcox joins LifeOmic from the US Department of Health and Human Services, where he served as chief technology officer and acting chief information officer. Prior to this, Simcox was director of US health care strategy, partnerships, and product development for AT&T. He also served as healthcare practice leader at Logicalis US, a global IT firm.
The Scottish Funding Council said this week that a country-wide precision medicine initiative in Scotland has received up to £9.5 million ($12.3 million) in new funding. The funding includes £7.5 million from the council and up to £2 million from Scottish Enterprise, and will support the growth of precision medicine in Scotland managed by the Precision Medicine Scotland Innovation Centre (formerly the Stratified Medicine Scotland Innovation Centre). The newly launched phase 2 of the center will continue to act as a catalyst for partnerships between industry, academia, and clinical entities. In phase 1 the Innovation Centre produced several large-scale projects in areas including ovarian cancer, rheumatoid arthritis, esophageal cancer, and multiple sclerosis. The center said it expects to be able to attract around £4.2 million in income from other sources.